These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV).
    Author: Rouffy J, Dreux C, Goussault Y, Dakkak R, Renson FJ.
    Journal: Arzneimittelforschung; 1976; 26(5):901-6. PubMed ID: 183788.
    Abstract:
    The effect of isopropyl-[4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl]-propionate (LF 178; procetofene; Lipanthyl), a new hypolipidemic agent, has been evaluated in 191 patients affected by endogenous hyperlipoproteinemia (IIa, IIb and IV). Data were collected from patients on active drug trial from 1 to 18 months. The daily administered dose varied from 200 to 400 mg according to pretreatment dietary stabilized lipid values. Under the controlled experimental conditions described, LF-178 lowered cholesterol by 20 to 36% in types IIa and IIb and triglycerides by 30 to 50% in types IIa and IV of H. L. P. A comparative trial of LF 178 and clofibrate indicates that the drug is significantly more potent than the reference compound after 1 month of treatment. Tolerance has always been excellent throughout the study.
    [Abstract] [Full Text] [Related] [New Search]